Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8184)
All Articles published online
|
Publishing Process of This Article
|
Dec 14, 2016 (publication date) through Dec 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016; 22(46): 10254-10259 [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i46/10254.htm |
| Number | Citing Articles |
| 1 |
D. Brock Hewitt, Zachary J. Brown, Timothy M Pawlik. Surgical management of intrahepatic cholangiocarcinoma. Expert Review of Anticancer Therapy 2022; 22(1): 27 doi: 10.1080/14737140.2022.1999809
|
| 2 |
Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, Nastassja Tober, Andrea Palloni, Veronica Mollica, Ilaria Maggio, Marzia Deserti, Simona Tavolari, Giovanni Brandi. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. Medicines 2020; 7(9): 54 doi: 10.3390/medicines7090054
|
| 3 |
Jing-Xiao Yang, Zi-Yao Jia, Fa-Tao Liu, Wen-Guang Wu, Xue-Chuan Li, Lu Zou, Huai-Feng Li, Fei Zhang, Run-Fa Bao, Shu-You Peng, Wan Yee Lau, Yun Liu, Mao-Lan Li, Ying-Bin Liu. Case report: A de novo ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1078388
|
| 4 |
Öykü Gönül Geyik, Giulia Anichini, Engin Ulukaya, Fabio Marra, Chiara Raggi. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells 2022; 11(9): 1463 doi: 10.3390/cells11091463
|
| 5 |
Taotao Zhou, Robert Mahn, Christian Möhring, Farsaneh Sadeghlar, Carsten Meyer, Marieta Toma, Barbara Kreppel, Markus Essler, Tim Glowka, Hanno Matthaei, Jörg C. Kalff, Christian P. Strassburg, Maria A. Gonzalez-Carmona. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.933943
|
| 6 |
Ahmad Al-Taee, Ammara Gill, Suzanne Mahon, Jinping Lai, Bassel Jallad. Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation. Journal of Gastrointestinal Cancer 2019; 50(1): 147 doi: 10.1007/s12029-017-9995-9
|
| 7 |
Jorge Adeva, Bruno Sangro, Massimiliano Salati, Julien Edeline, Adelaida La Casta, Alessandro Bittoni, Rossana Berardi, Jordi Bruix, Juan W Valle. Medical treatment for cholangiocarcinoma. Liver International 2019; 39(S1): 123 doi: 10.1111/liv.14100
|
| 8 |
Xin Yu Li, Jia Qi Chen, Adilai Aisa, Yu Wei Ding, Ding Zhang, Ying Yuan. Targeting BRCA‐mutant biliary tract cancer: Current evidence and future perspectives. Journal of Digestive Diseases 2023; 24(2): 85 doi: 10.1111/1751-2980.13168
|
| 9 |
Bhausaheb Bagal, Rohit Kumar, Tarang Gaur, Vikas Talreja, Avinash Bonda, Nikhil Patkar, Dhanlaxmi Shetty, Pradnya Kowtal, P. G. Subramanian, Sudeep Gupta, Rajiv Sarin, Syed K. Hasan. Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy. Medical Oncology 2020; 37(5) doi: 10.1007/s12032-020-01371-z
|
| 10 |
Ryosuke Okamura, Razelle Kurzrock, Robert J. Mallory, Paul T. Fanta, Adam M. Burgoyne, Bryan M. Clary, Shumei Kato, Jason K. Sicklick. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. International Journal of Cancer 2021; 148(3): 702 doi: 10.1002/ijc.33230
|
| 11 |
Matteo Canale, Manlio Monti, Ilario Giovanni Rapposelli, Paola Ulivi, Francesco Giulio Sullo, Giulia Bartolini, Elisa Tiberi, Giovanni Luca Frassineti. Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer. Cancers 2021; 13(22): 5671 doi: 10.3390/cancers13225671
|
| 12 |
Xiaofen Li, Limin Gao, Meng Qiu, Dan Cao. Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation. OncoTargets and Therapy 2021; : 2815 doi: 10.2147/OTT.S303594
|
| 13 |
Mao Li, Yu Mou, Shengzhong Hou, Dan Cao, Ang Li. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib. Medicine 2018; 97(45): e13113 doi: 10.1097/MD.0000000000013113
|
| 14 |
|
| 15 |
Zachary J. Brown, Daniel B. Hewitt, Timothy M. Pawlik. Gallbladder Cancer. 2023; : 75 doi: 10.1007/978-981-19-6442-8_4
|
| 16 |
James M. Bogenberger, Thomas T. DeLeon, Mansi Arora, Daniel H. Ahn, Mitesh J. Borad. Emerging role of precision medicine in biliary tract cancers. npj Precision Oncology 2018; 2(1) doi: 10.1038/s41698-018-0064-z
|
| 17 |
Vladimir Bezrookove, John M. Patino, Mehdi Nosrati, Pierre-Yves Desprez, Sean McAllister, Liliana Soroceanu, Ari Baron, Robert Osorio, Mohammed Kashani-Sabet, Altaf A. Dar. Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress. Cancers 2021; 13(17): 4405 doi: 10.3390/cancers13174405
|
| 18 |
Margherita Rimini, Teresa Macarulla, Valentina Burgio, Sara Lonardi, Monica Niger, Mario Scartozzi, Ilario G. Rapposelli, Giuseppe Aprile, Francesca Ratti, Federica Pedica, Helena Verdaguer, Floriana Nappo, Federico Nichetti, Eleonora Lai, Martina Valgiusti, Alessandro Cappetta, Carles Fabregat-Franco, Matteo Fassan, Filippo De Braud, Marco Puzzoni, Giovanni L. Frassineti, Francesca Simionato, Francesco De Cobelli, Luca Aldrighetti, Lorenzo Fornaro, Stefano Cascinu, Andrea Casadei-Gardini. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. European Journal of Cancer 2022; 171: 232 doi: 10.1016/j.ejca.2022.05.004
|
| 19 |
Rutika Mehta, Anthony C Wood, James Yu, Richard Kim. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opinion on Investigational Drugs 2021; 30(4): 451 doi: 10.1080/13543784.2021.1898586
|